Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial
暂无分享,去创建一个
Richard Degerman | Jonathan Mermin | Richard L. Degerman | J. Tappero | J. P. Ekwaru | A. Coutinho | R. Bunnell | Jordan Tappero | F. Kaharuza | J. Mermin | Rebecca Bunnell | Alex Coutinho | John P Ekwaru | Willy Were | Frank Kaharuza | Robert Downing | Peter Solberg | Lorraine N Alexander | James Campbell | David M Moore | David M. Moore | R. Downing | W. Were | L. Alexander | J. Campbell | P. Solberg | J. Campbell
[1] Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .
[2] M. Hirsch,et al. Monitoring HIV treatment in developing countries , 2006, BMJ : British Medical Journal.
[3] Mark Dybul,et al. Rapid expansion of the health workforce in response to the HIV epidemic. , 2007, The New England journal of medicine.
[4] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[5] T. Quinn,et al. Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy , 2007, Journal of acquired immune deficiency syndromes.
[6] R. Chaisson,et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] N. Ford,et al. HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] E. Nicastri,et al. Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAART , 2005, Journal of medical virology.
[9] T. Quinn,et al. Two-Year Virologic Outcomes of an Alternative AIDS Care Model: Evaluation of a Peer Health Worker and Nurse-Staffed Community-Based Program in Uganda , 2009, Journal of acquired immune deficiency syndromes.
[10] J. Tappero,et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study , 2008, The Lancet.
[11] A. Harries,et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi , 2008, Tropical medicine & international health : TM & IH.
[12] A. Phillips,et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. , 2008, The Journal of infectious diseases.
[13] B. Yip,et al. Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy , 2005, Journal of acquired immune deficiency syndromes.
[14] N. Parkin,et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.
[15] B. Yip,et al. Performance of Immunologic Responses in Predicting Viral Load Suppression: Implications for Monitoring Patients in Resource-Limited Settings , 2006, Journal of acquired immune deficiency syndromes.
[16] A. Breckenridge,et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial , 2010, The Lancet.
[17] Wasun Chantratita,et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Tze Leung Lai,et al. Modified Haybittle–Peto group sequential designs for testing superiority and non‐inferiority hypotheses in clinical trials , 2006, Statistics in medicine.
[19] Ross J. Harris,et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.
[20] A. Wensing,et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.
[21] P. Kaleebu,et al. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa , 2006, AIDS.
[22] K. Anastos,et al. Antiretroviral therapy in resource‐limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub‐Saharan Africa, Asia and Latin America , 2008, Tropical medicine & international health : TM & IH.
[23] K. Buchacz,et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda , 2006, The Lancet.
[24] N. Ford,et al. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. , 2007, The Journal of infectious diseases.
[25] A. Westfall,et al. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] P. Weidle,et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.
[27] H. Sørensen,et al. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. , 2006, Clinical Infectious Diseases.
[28] B. Chi,et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.
[29] N. Ford,et al. Scaling up antiretroviral treatment in resource-poor settings , 2006, The Lancet.
[30] Sydney Rosen,et al. Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review , 2007, PLoS medicine.
[31] Kara Wools-Kaloustian,et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.
[32] R. Rodrigues,et al. CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome. , 2004, AIDS patient care and STDs.
[33] N. Kumarasamy,et al. Generic antiretroviral drugs—will they be the answer to HIV in the developing world? , 2004, The Lancet.
[34] P. Farmer,et al. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience , 2004, AIDS.
[35] Deenan Pillay,et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model , 2008, The Lancet.
[36] Richard L. Degerman,et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study , 2011, BMJ : British Medical Journal.
[37] J. Sterne,et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.
[38] T. Quinn,et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda , 2009, AIDS.
[39] R. Stone,et al. Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries: The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration , 2007, Journal of acquired immune deficiency syndromes.
[40] B. Strom,et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy , 2006, AIDS.
[41] M. Dybul,et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda , 2009, Antiviral therapy.
[42] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[43] N. Ford,et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.